Pfizer Stock: Finally The Market Is Waking Up
Summary: Pfizer’s Q1 2023 results beat market forecasts, with strong revenue growth and cost management
Summary: Pfizer’s Q1 2023 results beat market forecasts, with strong revenue growth and cost management
Summary: Pfizer Inc. stock has taken a beating after its COVID-19 products experienced steep declines
Summary: Since my last article, the company’s share price has fallen about 10% despite its
Summary: PFE’s dividend has reached the sky-high (for a biotech) ~6% mark. Are the dividend
Summary: Given the huge and growing GLP-1 weight loss market, recent trial data from Viking
Summary: Pfizer has faced numerous challenges, including a decline in COVID-19 vaccine demand and high
Summary: Over the last twelve months, Pfizer’s stock experienced a massive sell-off due to a
Summary: Pfizer’s stock has dropped over the last year+ due to declines in revenue and
Summary: Pfizer’s share price has stabilized since the company provided 2024 revenue and EPS guidance
Summary: Pfizer’s Q4 FY2023 financials show a significant downturn in consolidated revenues, with a 93%